Wall Street holds firm on Intuitive Surgical despite 52-week underperformance
Intuitive Surgical shares have fallen 19.6% over the past year, lagging the S&P 500, yet a majority of covering analysts remain optimistic on the medical technology firm’s prospects.
Sunnyvale-based Intuitive Surgical has significantly underperformed the broader equity market over the past 52 weeks, with its shares declining 19.6 per cent. This stands in sharp contrast to the S&P 500 Index, which recorded a 27.4 per cent gain over the same period. On a year-to-date basis, the medical technology company’s stock is down 22.4 per cent, while the benchmark index has risen 8.7 per cent. The surgical robotics pioneer has also trailed the State Street Health Care Select Sector SPDR ETF, which gained 12.6 per cent over the past year but declined 4.3 per cent year-to-date.
Despite the sluggish share price action, a consensus of 30 Wall Street analysts maintains a "Moderate Buy" rating for the stock. This sentiment is anchored by robust first-quarter financial results released on 21 April, which saw revenue surge 23 per cent year-on-year to $2.8 billion. The top-line figure surpassed analyst forecasts by 5.8 per cent, while adjusted earnings per share reached $2.50, comfortably ahead of consensus estimates. The company also reported a notable improvement in profitability, with its adjusted operating margin expanding 4.4 percentage points to 38.4 per cent.
The strong earnings report initially sparked investor optimism, with shares surging 7.2 per cent in the trading session following the April 21 announcement. Intuitive Surgical has now exceeded consensus estimates in each of the last four quarters, reinforcing a track record of earnings surprises. For the current fiscal year ending in December, analysts project earnings per share to grow 18.7 per cent year-on-year to $8.57.
The composition of the analyst consensus has shifted slightly from two months ago, when 21 analysts held a "Strong Buy" rating. The current distribution comprises 19 "Strong Buy" ratings, two "Moderate Buy" ratings, eight "Hold" ratings, and one "Strong Sell" rating. This represents a marginally less bullish stance compared to the earlier period, though the majority of covering analysts remain positive on the stock’s long-term trajectory.
Price targets reflect a range of expectations, with the mean analyst target set at $583.23, implying a 32.6 per cent upside from current levels. The highest target on the street stands at $750, suggesting a potential 70.5 per cent gain. However, Bank of America recently adjusted its outlook, maintaining a "Buy" rating but lowering its price target to $520 on 18 May, which indicates an 18.2 per cent potential upside from recent trading levels.
